There is a long-running argument in health policy that pandemics should be classified and resourced as national security threats rather than as medical problems. The arithmetic behind it is hard to dispute: in the 250 years since America's founding, all the nation's wars combined claimed just over 1.3 million lives, while Covid-19 took over 1.2 million from 2020 to 2026.

The interesting question in 2026 is no longer whether that reframing will happen. It largely has. The question is what it produces, because securitization is not a neutral relabeling. It routes money, attention, and authority through institutions with their own priorities, and those priorities have a distinct shape.

The reframing is already institutional

Pandemic preparedness now sits inside national security architecture across multiple governments and agencies.

A 2026 executive order directs the National Security Council to undertake efforts to safeguard public health and fortify biosecurity, in lieu of WHO membership, while instructing the State Department and OMB to identify alternative international partners and ordering a review, rescission, and replacement of the 2024 U.S. Global Health Security Strategy.

Defense institutions have followed. The Department of Defense and alliances including NATO now treat biological threats as strategic risks, with emphasis on maintaining operational continuity and troop readiness during outbreaks. A February 2026 congressional hearing framed agricultural biosecurity as national resilience, supply-chain security, and strategic competition rather than a niche veterinary issue.

And funding is flowing through security-oriented channels. Federal officials at BIO 2026 pointed biotech companies toward the Biopharmaceutical Manufacturing Preparedness Consortium and the Rapid Response Partnership Vehicle for developing medical countermeasures, with an industry representative noting that many countermeasures needed against chemical, biological, radiological, and nuclear threats and emerging infectious diseases do not have a sustainable commercial market, making public-private partnerships essential.

That last point is the strongest practical argument for securitization, and it deserves emphasis. Countermeasures for rare catastrophic events have no commercial market by definition. Nobody buys a vaccine for a pathogen that has not emerged. Only a government purchaser with a security rationale sustains that capacity, and the defense budget is the only pot of money large enough and politically durable enough to do it year after year.

What the framing reliably funds

Look at what actually gets money once preparedness becomes security policy, and a consistent pattern emerges.

Medical countermeasures, meaning vaccines, therapeutics, and diagnostics developed against specified threats, get funded. Detection and surveillance infrastructure gets funded, particularly at borders and in agricultural systems. Supply chain resilience gets funded, since stockpiling essential supplies, diversifying supply chains, and strengthening domestic production map directly onto established defense-industrial thinking. Intelligence collection and interdiction get funded. Continuity of operations gets funded.

Every one of those is genuinely valuable, and several would not exist without the security framing.

What it reliably does not fund

Now the other column, and this is where the framing's limits show.

Securitization does not fund routine public health department staffing. It does not fund the hospital surge capacity that determines whether a regional outbreak becomes a mass-casualty event. It does not fund vaccination confidence or the communication infrastructure that determines whether countermeasures get used once they exist. It does not fund primary care access, which shapes how early people present with symptoms.

The Covid record makes the distinction concrete. Effective vaccines were developed in eleven months, a countermeasure triumph by any standard, and roughly 1.2 million Americans still died. The failures were substantially in distribution, trust, health system capacity, and coordination, not in the technology. A framework optimized for producing countermeasures would have gotten that part right and the rest wrong, which is approximately what happened.

There is a structural reason for the gap. National security institutions are organized around adversaries and discrete events. They are good at procuring specific capabilities against defined threats. They are poorly suited to sustaining diffuse, continuous, locally administered public capacity, which looks like ordinary government spending rather than defense, and which no one can point to as a deliverable.

The threat-selection problem

Securitization also shifts which threats get priority, and the shift runs in a specific direction.

The 2026 biological threat landscape is described as defined by concealment, dual-use research, weak verification, and the rapid diffusion of enabling technologies, with policy debate focused on strengthening the Biological Weapons Convention against contemporary realities.

Those are real concerns. They are also concerns about deliberate action by adversaries, which is what security institutions are built to think about. Natural spillover events, which historically cause the overwhelming majority of pandemics, do not have an adversary, do not respond to deterrence, and do not fit the analytical frameworks that make security agencies effective.

An intelligence-led posture will tend to allocate attention toward the deliberate end of the spectrum, because that is where intelligence has purchase. The empirical distribution of pandemic risk points the other way. Preparedness aimed at both is possible, and the two share some infrastructure, detection and countermeasure platforms serve either origin, but the resource split will not follow the risk split unless someone insists on it.

There is a related benefit worth granting, though: an agnostic posture. Some biodefense scholars argue for bioagent-agnostic signatures rather than approaches based on priority agent lists precisely because listing specific threats fails against novel ones. That approach, if adopted, would serve natural and deliberate threats equally, and it is the design choice that determines whether securitization narrows preparedness or broadens it.

The cooperation cost

The least discussed downside is diplomatic. Framing pathogens as a security matter changes how other countries respond to requests for samples, sequence data, and outbreak access.

Public health cooperation runs on a norm of shared scientific interest. Security cooperation runs on interest calculation and reciprocity. When a country's disease surveillance is understood as an intelligence activity, other governments have reasons to restrict access that they would not have toward a health agency, particularly if they suspect the data will inform threat assessments about them.

The 2026 posture makes this sharper: stepping back from WHO membership while directing the NSC to fortify biosecurity and seek alternative international partners substitutes bilateral, interest-based arrangements for multilateral scientific ones. That may prove more effective or less, but it is a different instrument, and early warning about a novel pathogen depends on a foreign scientist's willingness to share an unusual finding quickly. That willingness is a function of trust in the receiving institution.

The dual-use problem the framing cannot resolve

One thing securitization genuinely does address, and cannot fully solve, is that preparedness and threat share a technology base. The research enabling rapid countermeasure development is the research raising concern about dual-use work and the diffusion of enabling technologies. Computational tools now sit inside this question too, with biosecurity convenings examining how science and technology competition across AI, high performance computing, and advanced manufacturing affects both threat and response.

A security framework is arguably better equipped than a health framework to handle this, since it has existing machinery for classification, export controls, and access restriction. It is also more likely to apply those tools broadly, which slows the open scientific exchange that produced the Covid vaccines in eleven months. That is a genuine trade-off with no clean answer, and it should be argued explicitly rather than settled by which agency happens to hold the budget.

The useful version of the argument

The case for treating pandemics as national security threats is strong on its merits: the mortality arithmetic is decisive, the funding is otherwise unavailable, and countermeasure markets do not exist without a government buyer.

But the framing should be adopted with clear sight of what it does. It buys stockpiles, countermeasures, detection systems, and interagency coordination. It does not buy public health departments, hospital surge capacity, or public trust, and those determined the outcome last time. A country that securitizes preparedness and then treats ordinary public health funding as a separate, lower-priority category will be excellent at producing a vaccine and mediocre at getting it into people, which is the specific failure it just lived through. Securitization is necessary and insufficient, and it should not be allowed to substitute for the unglamorous capacity that no security budget will ever describe as a deliverable.

Further reading